Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells

BACKGROUND: Cervical cancer (CC) annually kills 288 000 women worldwide. Unfortunately, responses to chemoradiation are partial and are of short duration. As anti-EGFR monoclonal antibodies sensitise tumours, we investigated cetuximab's toxicity plus chemoradiation on CC cells, which express di...

Descripción completa

Detalles Bibliográficos
Autores principales: Meira, D D, de Almeida, V H, Mororó, J S, Nóbrega, I, Bardella, L, Silva, R L A, Albano, R M, Ferreira, C G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736849/
https://www.ncbi.nlm.nih.gov/pubmed/19654571
http://dx.doi.org/10.1038/sj.bjc.6605216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736849/
https://www.ncbi.nlm.nih.gov/pubmed/19654571
http://dx.doi.org/10.1038/sj.bjc.6605216

Ejemplares similares